

A Panel of Diverse *Klebsiella pneumoniae* Clinical Isolates for Research and Development

Melissa J. Martin^a, William Stribling^a, Ana C. Ong^a, Rosslyn Maybank^a, Yoon I. Kwak^a, Joshua A. Rosado-Mendez^a, Lan N Preston^a, Katharine F. Lane^a, Michael Julius^a, Anthony R. Jones^b, Mary Hinkle^c, Paige E. Waterman^d, Emil P. Lesho^c, Francois Lebreton^a, Jason W. Bennett^a, and Patrick T. McGann^a

^aMultidrug-Resistant Organism Repository and Surveillance Network, Walter Reed Army Institute of Research, Silver Spring Maryland, USA

^bDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

^cInfectious Diseases Unit, Rochester General Hospital, Rochester New York, USA

^dDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Keywords: *Klebsiella pneumoniae*, antimicrobial resistance, whole-genome sequencing, convergent

Short title: Diverse *K. pneumoniae* strain set

[#]Address correspondence to Patrick T. McGann, patrick.t.mcgann4.civ@mail.mil
Walter Reed Army Institute of Research
503 Robert Grant Avenue, 2A36
Silver Spring, MD 20910, USA

Importance

Klebsiella pneumoniae is a major cause of healthcare-associated infections that are increasingly difficult to treat due to the emergence of multi-drug resistant strains. In particular, strains expressing extended-spectrum β -lactamases and carbapenemases have attained global notoriety, with the World Health Organization listing these strains as a “critical-priority” for the development of new therapeutics. Access to a diverse collection of strains for testing is critical for this endeavor, but few resources currently exist. Similarly, pivotal research of the genetic determinants underlying the pathogenesis of hypervirulent lineages is hampered by the lack of standardized, comparator strains. Herein we describe a panel of 100 diverse *K. pneumoniae* constructed to maximize genetic and phenotypic diversity from a repository of over 3,800 clinical isolates collected over 19 years. The panel, and all associated metadata and genome sequences, is provided at no cost and will greatly assist efforts by academic, government, and industry research groups.

Abstract

Klebsiella pneumoniae are a leading cause of healthcare associated infections worldwide. In particular, strains expressing extended-spectrum β -lactamases (ESBLs) and carbapenemases pose serious treatment challenges, leading the World Health Organization (WHO) to designate ESBL and carbapenem-resistant Enterobacteriaceae (CRE) as “critical” threats to human health. Research efforts to combat these pathogens can be supported by accessibility to diverse and clinically relevant isolates for testing novel therapeutics. Here, we describe a panel of 100 diverse *K. pneumoniae* isolates publicly available to assist the research community in this endeavor.

Whole-genome sequencing (WGS) was performed on 3,878 *K. pneumoniae* clinical isolates housed at the Multidrug-Resistant Organism Repository and Surveillance Network. The isolates were cultured from 63 facilities in 19 countries between 2001 and 2020. Core-genome multilocus sequence typing and high-resolution single nucleotide polymorphism based phylogenetic analyses captured the genetic diversity of the collection and were used to select the final panel of 100 isolates. In addition to known multi-drug resistant (MDR) pandemic lineages, the final panel includes hypervirulent lineages and isolates with specific and diverse resistance genes and virulence biomarkers. A broad range of antibiotic susceptibilities ranging from pan-sensitive to extensively drug resistant isolates are described. The panel collection, all associated metadata and genome sequences, are available at no additional cost and will be an important for the research community and for the design and development of novel antimicrobial agents and diagnostics against this important pathogen.

Introduction

Klebsiella pneumoniae are a leading cause of nosocomial infections resulting in pneumonia, bacteremia, surgical site, and urinary tract infections (1). A member of the problematic ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacter*) group of pathogens (2), “classical” *K. pneumoniae* (cKp) are associated with prolonged outbreaks, increased disease burden, and high mortality rates (3, 4). The prevalence of cKp infections has steadily increased since 2005, primarily driven by strains acquiring extended-spectrum β -lactamases (ESBLs) and carbapenemases conferring resistance to 3rd generation cephalosporins and carbapenem antibiotics (5, 6). These multidrug resistant (MDR)-cKp clones are a threat to the medical community as antibiotic treatment options are limited and non-susceptibility to all antibiotics has been reported (7). In alignment, the World Health Organization (WHO) ranks *K. pneumoniae* among the critical priority list for the development of therapeutics (8).

In parallel to hospital-acquired MDR-cKp, severe community-acquired infections caused by so called “hypervirulent” *K. pneumoniae* (hvKp) lineages have also emerged (9). These invasive strains are generally susceptible to antibiotics and generally occur in healthy hosts causing meningitis, liver abscesses, endophthalmitis, and soft tissue infections (9). hvKp strains are associated with the acquisition of large virulence plasmids and/or mobile elements encoding virulence determinants such as siderophores [e.g aerobactin (*iuc*), salmochelin (*iro*), yersiniabactin (*ybt*)], metabolite transporter *peg-344*, genotoxic polyketide colibactin (*clb*), and regulators of mucoviscosity and capsular polysaccharide (*rmpA* and *rmpA2*) (10, 11). While there are distinct clinical and genetic differences between the two main pathotypes of *K. pneumoniae*, there has been a concerning emergence of convergent lineages that carry both MDR

and virulence determinants (12–14). This confluence of MDR-cKp and hvKp has provided additional impetus to develop novel antibiotics and therapeutics (15).

The *K. pneumoniae* population is diverse consisting of over 250 clonal phylogenetic lineages and an estimated accessory genome of >100,000 protein coding sequences (6, 16). Despite hundreds of clones that can cause infections, a few “high-risk”, globally disseminated, MDR-cKp lineages (e.g. ST-11, ST-14, ST-101, ST-147, ST-258, ST-307) contribute to the majority of infections (6). For example, the dissemination of KPC-type carbapenemases is largely attributed to the well-studied, clonal ST-258 lineage, which is now endemic in many countries, including the United States (17–19). More recently, carbapenem resistant ST-307 and ST-147 clonal lineages carrying various carbapenemases (NDMs, OXA-48-like, and KPC) have emerged and are circulating in countries such as the United States (19), Germany (20), and in Italy (21). In contrast, unrelated hvKp lineages are mainly described from the Asian Pacific Rim countries and are predominately ST-23, ST-86, ST-65, ST-380, and ST-66 lineages (6, 9). These hvKp strains are associated with very few capsular polysaccharide types K1, K2, and/or K5, in contrast to the substantial diversity of K-loci found in cKp strains (22). The significant genomic diversity and constantly changing epidemiology highlights the importance of using the *K. pneumoniae* population structure for identifying diverse isolates when developing effective targets for treatments and diagnostics against problematic MDR-cKP, hvKp, and emerging clones.

In this report, we utilized the large repository of 3,878 clinical *K. pneumoniae* maintained by the Multidrug-Resistant Organism Repository and Surveillance network (MRSN) (23) and collected globally between 2001 and 2020. Comparable to our previous work (24, 25) we constructed a reference panel of 100 *K. pneumoniae* clinical isolates that captures the extensive genetic diversity of this species, as well as variable antibiotic resistance gene content and virulence gene

105 content along with a wide range of antimicrobial susceptibility profiles. This panel is available to
106 the research community at no extra cost to aid in the design and development of novel
107 therapeutics and diagnostics for this critical pathogen.

108

Results

Global *K. pneumoniae* population structure and collection diversity

3,878 *K. pneumoniae* clinical isolates were collected over a 19-year period (2001 to 2020) from across the U.S. and globally in collaboration with the U.S. Department of Defense's Global Emerging Infections Surveillance (GEIS) branch. After removal of serial isolates from the same patients, 3,123 primary isolates from 2,760 patients were analyzed by core-genome multilocus sequence typing (cgMLST) to generate a minimum spanning tree revealing the genomic diversity of the population (**Fig. 1A**). The isolates were recovered from 63 healthcare facilities across 6 continents including North America (63%), Asia (17.6%), Europe (8.9%), South America (5.0%), Africa (4.7%), and Oceania (0.4%). The majority were cultured from urine (46%), followed by respiratory (11%), perianal surveillance swabs (10%), wound (9%), blood (9%), and body fluid (2%) cultures. *In silico* MLST using the scheme designed by Diancourt *et al.* (26) identified 480 ST's with 260 (54%) found in isolate(s) from a single patient. Despite the large number of ST's, 34% of the isolate collection is represented by 6 globally problematic clones: ST-15 (7.8%), ST-147 (5.9%), ST-258 (5.8%), ST-307 (5.3%), ST-14 (4.8%), and ST-16 (4.6%) (6). Clonal lineages were associated with lower allelic diversity (e.g. ST-258 maximum of 87 allelic differences) however, extensive diversity was observed within other lineages (e.g. 1,312 allelic differences within ST-37) (**Fig. 1A**).

Selection of a nonredundant, genetically diverse panel of *K. pneumoniae*

Based on the cgMLST analysis, an initial subset of 346 isolates (11%) was selected to represent the maximum genetic diversity of the collection and to minimize clonal redundancy (**Fig. 1A, red dots**). This subset, encompassing 143 STs, was further compared using a maximum likelihood single nucleotide polymorphism (SNP)-based phylogenetic tree (**Fig. 1B**). In an effort

to provide a pragmatic panel, 100 isolates were selected from the subset and analyzed by core genome SNP-based phylogeny (**Fig. 2 and Table S1**). This final panel of 100 isolates encompassed 94 STs, including 6 novel ST's, and retained substantial diversity in gene content. The core genome encompassed 3,034 genes with the pangenome consisting of 21,419 genes (**Fig. S1**). Similar to previous studies (27, 28), the most prevalent predicted O antigen types, involved in the composition of cell surface lipopolysaccharide, were O1, O2, and O3, which were found in 81% of the panel isolates, followed by types O4 (10%), O5 (5%), and unknown (4%) (**Table S1**). The panel also contains 54 distinct capsular polysaccharide types, with K2 type being the most prevalent ($n = 7$).

Distinct virulence gene content in the *K. pneumoniae* panel isolates

Acquired *K. pneumoniae* virulence loci associated with the hvKp pathotype were characterized in the panel isolates. Thirty isolates in the final panel carried the *ybt* siderophore gene cluster found on chromosomally inserted integrative conjugative elements (ICEKp). The ICEKp3 lineage (encoding *ybt9* sequence type) was the most prevalent and found in 8 isolates from ST-11, ST-15, ST-16, ST-101, ST-147, ST-307, ST-340, and ST-1271 (**Table S1**). Seven isolates carried *clb*, encoding the genotoxic colibactin, in conjunction with *ybt* (lineage 1, 12, and/or 17) that were associated with the ICEKp10 lineage, as previously described (29). The *iro* gene cluster encoding salmochelin synthesis and the regulators for hypermucoidy and capsule expression, *rmpA* and/or *rmpA2*, were identified in 3 isolates. Notably, 8 isolates harbored the aerobactin-encoding *iuc* genes, including 2 known hvKp lineages (ST-380 and ST-86) with the predicted serum resistant K2 capsular serotype (22). Further, 6 isolates carried the *iuc* loci in addition to ESBL genes (*bla*_{CTX-M-14} or *bla*_{CTX-M-15}) (**Fig. 1C**). Alarming, 2 of these genotypic

convergent isolates also carried the *bla*_{NDM-1} carbapenemase including the recently characterized epidemic ST-147 isolate, MRSN 752729, from a nosocomial outbreak in Italy (12).

AMR gene content and antimicrobial susceptibilities of the final panel

64 distinct antibiotic susceptibility profiles were observed in the final 100 isolate panel (**Fig. 2 and Table S1**). Using the susceptibility criteria developed by Magiorakos *et al.* (30), 1 isolate was pan drug resistant (PDR), 28 were extensively drug resistant (XDR), 46 isolates were MDR, 7 were non-MDR, and 19 were pan-susceptible to all antibiotics tested. Notably, 56 isolates were non-susceptible to the 3rd generation cephalosporins tested (ceftazidime and ceftriaxone), 24 were non-susceptible to carbapenems (imipenem and meropenem), and 10 were non-susceptible to the newer β -lactam/ β -lactamase inhibitor, ceftazidime-avibactam.

Overall, AMR genes known to confer non-susceptibility were detected in all 100 genomes with 135 distinct alleles identified from 40 antibiotic families (**Table S1**). The majority of intrinsic *bla*_{SHV} class-A β -lactamase alleles detected were *bla*_{SHV-1} and/or *bla*_{SHV-11} (16). In 59 isolates, *bla*_{SHV} and/or *bla*_{CTX-M} ESBLs were detected, with *bla*_{CTX-M-15} (*n* = 44) being the most prevalent. Three isolates (MRSN 750999, 680172, 27106) carried *bla*_{SHV-27} as their sole ESBL gene (31), but were susceptible to the 3rd generation cephalosporins. The *bla*_{GES-5} ESBL was found in a single isolate, MRSN 28183, resulting in non-susceptibility to 3rd generation cephalosporins and ceftolozane-tazobactam.

Carbapenemase genes encoding IMP, KPC, NDM, OXA-48-like, and VIM enzymes were present in 24 isolates. Eleven isolates produced OXA-48-like β -lactamases (OXA-48, -181, -232) capable of hydrolyzing carbapenem antibiotics, with OXA-48 being the most common (*n* = 7). All OXA-48-like positive isolates co-produced the ESBL CTX-M-15 (except a single isolate, MRSN 13748, with CTX-M-14) and as expected were non-susceptible to ceftazidime, cefepime,

aztreonam, imipenem, and meropenem. Three OXA-48-like carrying isolates also co-produced NDM-1 or -5 enzymes including lineages ST-147, ST-16, and the well-studied hvKp lineage ST-23 (**Table S1**). As expected, all 10 isolates carrying genes encoding the Ambler class B Metallo- β -lactamases (MBL; IMP, NDM and VIM variants) were non-susceptible to ceftazidime-avibactam. As carbapenemase non-susceptibility can also be mediated through mutations in the outer membrane proteins (OmpK35 and/or OmpK36) in conjunction with the expression of an ESBL and/or acquired AmpC β -lactamases (32, 33), all strains were examined for known mutations in these genes. Variations in OmpK35 and/or OmpK36 were observed in 15 isolates, of which 12 carried a carbapenemase and were non-susceptible to all carbapenem antibiotics tested. The remaining three isolates had OmpK35 mutations only and were susceptible to the carbapenems. In the final panel, only 4 isolates carried an acquired AmpC β -lactamase (*bla*_{FOX-5}, *bla*_{DHA-1}, or *bla*_{CMY-4}) and all lacked OmpK mutations. Notably, 7 isolates had a truncated *mgrB*, known to mediate colistin resistance (**Table S1**), and five were resistant (MIC > 4) to colistin by broth microdilution (BMD). As the Clinical and Laboratory Standards Institute (CLSI) guidelines (34) do not recognize susceptible breakpoints for colistin the remaining two isolates with a truncated *mgrB* (791403 and 375436) were assigned intermediate interpretation (MIC $\leq$ 0.25 and 1, respectively), as reported previously (12).

Forty-two isolates were susceptible to all three aminoglycosides tested (amikacin, gentamicin, and tobramycin) while 9 isolates were pan resistant to all aminoglycosides. All pan resistant isolates carried a 16S rRNA methyltransferase, with the exception of MRSN 430405 for which no acquired methyltransferase gene was identified (**Table S1**). Specifically, five of the pan resistant isolates (5881, 366562, 365679, 517281, and 613682) carried methyltransferase genes *rmtH*, *rmtF1*, or *rmtB1* and the remaining three (MRSN 27778, 607210, 368001) carried *armA*. MRSN

200 752729 also carried *armA* but was susceptible to amikacin and gentamicin. Reduced
201 susceptibility was confirmed by BMD (amikacin, MIC=16; gentamicin, MIC=1). Further
202 analysis of the *armA* sequence revealed a missense mutation at nucleotide position 617 (A to T)
203 resulting in an amino acid substitution of isoleucine to lysine.

Discussion

In 2017, the WHO identified ESBL and carbapenemase-resistant Enterobacteriaceae as a “Critical” threat to human health. Similarly, the U.S. CDC named carbapenem-resistant and ESBL-producing Enterobacterales as “urgent” and “serious” threats, respectively (35). As a result, there has been a renewed and concerted effort to develop novel therapeutics and diagnostics to combat these organisms. This has been reflected at the highest level of the U.S. Government with the publication of the Presidential U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) (36). This document outlined strategies to combat this threat, including access to diverse isolates for testing. In response to these demands, the U.S. Department of Defense, through the MRSN, has published distinct panels (with corresponding metadata and genomes) for the ESKAPE pathogens *Acinetobacter baumannii* (24) and *Pseudomonas aeruginosa* (25). Herein we expand these panels by constructing a novel panel of *K. pneumoniae* isolates that, to our knowledge, is the only comprehensive panel publicly available for research and development. The panel was designed to encompass the maximum genetic diversity of the species, ensuring a diverse range of antibiotic susceptibilities, AMR genes and virulence genes.

Other panels and characterized *K. pneumoniae* strains exist, however, they mainly focus on the identification of antibiotic resistant mechanisms and were not designed to encompass the diversity of the species. For example, the U.S. CDC and FDA have collaborated to produce the AR Isolate Bank that contains multiple isolate panels for a range of bacterial pathogens and resistance mechanisms (<https://wwwn.cdc.gov/ar isolate bank/Overview>) and this panel has proven to be an excellent resource to test the activity of antibiotic combinations (37). However, in addition to testing antibiotics, strain diversity is critical for assessing the efficacy of many

emerging therapeutics including phage therapy, vaccines, and capsule polysaccharides targeted approaches (38–40). The main structural receptor for anti-*Klebsiella* phages is the external capsular polysaccharide however recent work suggests that phages also attach to other outer membrane structures below the capsule, including the O-antigen (41, 42). The panel described herein represents 54 of the 77 distinct capsule types identified by serological methods (43) and 8 predicted O serotypes (27, 44), providing a robust representation of outer membrane protein diversity to test anti-*Klebsiella* phages. Besides therapeutics, the understanding of *K. pneumoniae* pathogenesis is rapidly evolving, in particular the understanding of virulence factors that can accurately predict pathogenic potential of strains. For example, not all hvKp strains are equally virulent in murine models of infection despite carrying well-characterized virulence biomarkers (45). Herein we describe hvKp and convergent strains with diverse biomarkers to aid in these ongoing research efforts.

The epidemiology of *K. pneumoniae* over the past two decades has been characterized by widely geographically distributed “high risk” clones and the constant emergence and dissemination of new clonal groups (6). This panel not only captures the most important MDR-cKp (ST-258, ST-15, ST-11, ST-307, ST-147) and hvKp clones (ST-23, ST-380, ST-65, ST-86) currently circulating, but also encompasses the overall diversity of the species, an approach that maximizes the potential of the panel to include emerging strains, or those that may emerge in the future. To this end, the panel includes 6 novel lineages, including an XDR ST-5445 lineage carrying *bla*_{CTX-M-15}, and 5 genomic convergent lineages that have not been previously described (ST-268, ST-1399, ST-48, ST-2071, ST-37). Furthermore, close attention was paid to selecting rare clones that cause localized epidemics in different regions of the world. Clones ST-43, ST-268, ST-340, ST-392 are all represented in the panel and have been reported previously as

harboring NDM carbapenemases and circulating in hospitalized patients in Iran (46). Similarly, a ST-340 clone carrying a NDM carbapenemase was recovered from patients at a tertiary care hospital in South Korea (47) and infections with ST-231 and/or ST-395 clones have been identified in local hospitals in Oman (48) and South India (48, 49). A genomic surveillance study from 2013 to 2014 found ST-231, ST-340, ST-323 (carrying various ESBLs and carbapenemase genes) clones all linked to nosocomial transmission events from 4 hospitals in Melbourne Australia (50). In our panel collection the XDR clone ST-340 was collected in Asia in 2015 while the MDR clones ST-323 and ST-231 were recovered from North America in 2016 and 2018, respectively. Interestingly these localized epidemic clones have yet to globally disseminate despite being highly antibiotic resistant.

Notably, a strong association between antibiotic susceptibility and the presence of AMR genes and/or mutations was observed, with few exceptions. For example, isolates carrying *bla*_{SHV-27} ESBL had a non-ESBL phenotype. However, this discrepancy is most likely due to a base-pair substitution (A to C) in the promoter region that was previously reported in SHV-27-producing isolates susceptible to cephalosporins (51). Similarly, isolate MRSN 752729 carrying a missense mutation in *armA* 16s rRNA methyltransferase had increased susceptibility to all aminoglycoside antibiotics. Previous studies report that point mutations in *armA* can result in the inability to bind to the 16S rRNA and consequently block methylation resulting in susceptibility to aminoglycosides (52). Lastly, in this study the single GES-5-producing isolate (MRSN 28183) conferred non-susceptibility to ceftazidime, ceftriaxone, and ceftolozane-tazobactam but was susceptible to cefepime and carbapenem antibiotics. The GES-5 variant has a single amino acid substitution (G170S) compared to wild-type GES-1 and has been shown to confer activity against carbapenem antibiotics (53), yet, studies have also shown GES-5 producing *K.*

pneumoniae to have minimal to no carbapenemase activity (54, 55), consistent with our observations.

In summary, this study describes the construction of a panel of 100 unique *K. pneumoniae* isolates from an extensive collection of over 3,800 *K. pneumoniae* isolates collected from across the globe. The panel encompasses the diversity of the species, includes both antibiotic susceptible and non-susceptible isolates, and captures known epidemic clones as well as sporadic ones. Furthermore, this panel captures diverse genomic convergent and hvKp strains that are rapidly emerging worldwide and are of considerable concern (15, 45). While identifying these convergent lineages does not accurately predict clinical outcomes, availability of these characterized isolates (including phylogeny, genome, and AST) will aid in the research and development of infection-control measures to improve patient care. This panel and all metadata and genomes are publicly available at no additional charge and represent an invaluable resource for genotypic and phenotypic research of this important pathogen.

Materials and Methods

***K. pneumoniae* repository.** The MRSN collects and analyzes MDR organisms across the Military Healthcare System in the United States (23) and around the world in collaboration with the US Department of Defense's (DoD) Global Emerging Infections Surveillance (GEIS) branch. All samples are housed in a central repository, which currently contains over 100,000 isolates, including 3,878 *K. pneumoniae* that were cultured from 2,760 patients between 2001 and 2020.

Refinement of *K. pneumoniae* repository. To reduce redundancy in the initial 3,878 isolate set, successive isolates after the first from the same patient that shared the same ST were removed unless isolates were cultured from a different body site (e.g. urine vs blood) or were cultured >6 months apart. All isolates from the same patient with different STs were retained. This refinement resulted in a final dataset of 3,123 isolates available for analysis.

Antibiotic susceptibility testing. AST was performed in the MRSN's College of American Pathologists (CAP)-accredited laboratory using the Vitek 2 with the AST-95 and AST-XN09 cards (bioMerieux, NC, US). Nineteen antibiotics representing 11 different antibiotic families were tested and interpreted using Clinical and Laboratory Standards Institute (CLSI) guidelines (CLSI 2018). Susceptibility results were used to classify the isolates as pan drug resistant (PDR) (non-susceptible to all antibiotics tested), extensively drug resistant (XDR) (non-susceptible to ≥ 1 agent in all but ≤ 2 families), MDR (non-susceptible to ≥ 1 agent in ≥ 3 antibiotic families), and non-MDR (non-susceptible to 1 or 2 categories) using a modification of the criteria defined by Magiorakos et al (30). When necessary, MICs were repeated in triplicate using broth microdilution and CLSI guidelines (CLSI 2018).

Whole-genome sequencing and data analysis. Briefly, isolates were sequenced on an Illumina MiSeq or NextSeq benchtop sequencer (Illumina, Inc., CA, US) and analyzed as previously

described (24). Where appropriate, long read sequencing was performed with the Oxford nanopore MinION sequencer (Oxford Nanopore Technologies), as previously described (12). *In silico* MLST typing, virulence loci, polysaccharide capsule (K) loci, and lipopolysaccharide (O) loci typing were performed using Kleborate v2.0.1 (56). Novel MLST STs were determined using the Klebsiella PasteurMLST sequence database (<https://bigsd.b.pasteur.fr/klebsiella>). AMRFinderPlus v3.9.8 (57) and ARIBA v2.14.4 (58) were used to identify resistance alleles. Basic assembly statistics are available (see **Table S2** in the supplemental material).

cgMLST analysis. The draft genomes of all 3,878 *K. pneumoniae* isolates were uploaded and analyzed using Ridom SeqSphere+ (59) using the *K. pneumoniae* cgMLST scheme (<https://www.cgmlst.org/ncs>). To be included in the analysis, isolates had to contain 90% of the 2,358 genes included in the cgMLST scheme. The resulting minimum spanning tree (MST) was then used to select 346 strains that capture the diversity of the strain collection.

Core-genome SNP analysis. PanSeq (60) was run with a fragmentation size of 500 bp to find sequences with $\geq 95\%$ identity in $\geq 95\%$ of the isolates to generate the core genome single nucleotide polymorphism (SNP) alignment for the initial set of 346 isolates. RAxML (v8.2.11) (61) was used to generate a phylogenetic tree for the core SNP alignment. The SNP-based phylogeny was built from a 317-kb variable position alignment using the general time reversible (GTR) GAMMA model and the rapid bootstrapping option for nucleotide sequences, using 100 replicates. Using this approach, 100 strains were selected to represent the final diversity panel. For the final diversity set of 100 isolates, reads were checked for contamination at the species level with Kraken2 (v2.0.8-beta) (62) and at the strain level using ConFindr (v0.4.8) (63) with parameters $bf=0.05$ and $q=30$, as previously described (24). A phylogenetic tree of the 100 isolates was constructed with PanSeq and RAxML as described above. The SNP-based

332 phylogeny was built from 169-kb variable position alignment. For all 100 isolates included in the
 333 panel, genome annotations were performed using NCBI Prokaryotic Genome Annotation
 334 Pipeline (v4.8) and core and pangenomes were calculated with Roary (v3.12.0) (64). The final
 335 100 genomes have been deposited in the National Center for Biotechnology Information under
 336 BioProject PRJNA717739.

337 **Diversity panel availability.** The final *K. pneumoniae* diversity panel has been deposited at BEI
 338 resources (<https://www.beiresources.org/>) and is currently available for research purposes under
 339 catalogue #NR-55604.

Acknowledgements

This study was funded by the U.S. Army Medical command, the Defense Medical Research and Development Program and the Department of Defense (DoD) Global Emerging Infections Surveillance (GEIS) program (Award P0140_20_WR_04 to J.W. Bennett and P.T. McGann).

We gratefully acknowledge the participation of clinical laboratories across the Military Healthcare System, GEIS-affiliated overseas laboratories, and numerous collaborators for their contributions of bacteria to the MRSN repository.

The manuscript has been reviewed by the Walter Reed Army Institute of Research and there is no objection to its presentation. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

References

1. Podschun R, Ullmann U. 1998. *Klebsiella* spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors. Clin Microbiol Rev 11:589–603.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12.
3. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleeschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Strauss R, Mertens K, Struyf T, Catry B, Latour K, Ivanov IN, Dobрева EG, Tambic Andrašević A, Soprek S, Budimir A, Paphitou N, Žemlicková H, Schytte Olsen S, Wolff Sönksen U, Märtin P, Ivanova M, Lyytikäinen O, Jalava J, Coignard B, Eckmanns T, Abu Sin M, Haller S, Daikos GL, Gikas A, Tsiodras S, Kontopidou F, Tóth Á, Hajdu Á, Guólaugsson Ó, Kristinsson KG, Murchan S, Burns K, Pezzotti P, Gagliotti C, Dumpis U, Liuimienė A, Perrin M, Borg MA, de Greeff SC, Monen JC, Koek MB, Elstrøm P, Zabicka D, Deptula A, Hryniewicz W, Caniça M, Nogueira PJ, Fernandes PA, Manageiro V, Popescu GA, Serban RI, Schréterová E, Litvová S, Štefkovicová M, Kolman J, Klavs I, Korošec A, Aracil B, Asensio A, Pérez-Vázquez M, Billström H, Larsson S, Reilly JS, Johnson A, Hopkins S. 2019. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19:56–66.
4. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC, Browne AJ, Chipeta MG, Fell F, Hackett S, Haines-Woodhouse G, Kashef Hamadani BH, Kumaran EAP, McManigal B, Agarwal R, Akech S, Albertson S, Amuasi J, Andrews J, Aravkin A, Ashley E, Bailey F, Baker S, Basnyat B, Bekker A, Bender R, Bethou A, Bielicki J, Boonkasidecha S, Bukosia J, Carnevalheiro C, Castañeda-Orjuela C, Chansamouth V, Chaurasia S, Chiurchiù S, Chowdhury F, Cook AJ, Cooper B, Cressey TR, Criollo-Mora E, Cunningham M, Darboe S, Day NPJ, De Luca M, Dokova K, Dramowski A, Dunachie SJ, Eckmanns T, Eibach D, Emami A, Feasey N, Fisher-Pearson N, Forrest K, Garrett D, Gastmeier P, Giref AZ, Greer RC, Gupta V, Haller S, Haselbeck A, Hay SI, Holm M, Hopkins S, Iregbu KC, Jacobs J, Jarovsky D, Javanmardi F, Khorana M, Kissoon N, Kobeissi E, Kostyanov T, Krapp F, Krumkamp R, Kumar A, Kyu HH, Lim C, Limmathurotsakul D, Loftus MJ, Lunn M, Ma J, Mturi N, Munera-Huertas T, Musicha P, Mussi-Pinhata MM, Nakamura T, Nanavati R, Nangia S, Newton P, Ngoun C, Novotney A, Nwakanma D, Obiero CW, Olivas-Martinez A, Oliaro P, Ooko E, Ortiz-Brizuela E, Peleg AY, Perrone C, Plakkal N, Ponce-de-Leon A, Raad M, Ramdin T, Riddell A, Roberts T, Robotham JV, Roca A, Rudd KE, Russell N, Schnall J, Scott JAG, Shivamallappa M, Sifuentes-Osornio J, Steenkeste N, Stewardson AJ, Stoeva T, Tasak N, Thaiprakong A, Thwaites G, Turner C, Turner P, van Doorn HR, Velaphi S, Vongpradith A, Vu H, Walsh T, Waner S, Wangrangsimakul T, Wozniak T, Zheng P, Sartorius B, Lopez AD, Stergachis A, Moore C, Dolecek C, Naghavi M. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet 399:629–655.

- 394 5. Navon-Venezia S, Kondratyeva K, Carattoli A. 2017. *Klebsiella pneumoniae*: a major
395 worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41:252–275.
- 396 6. Wyres KL, Lam MMC, Holt KE. 2020. Population genomics of *Klebsiella pneumoniae*.
397 Nat Rev Microbiol 18:344–359.
- 398 7. Chen L, Todd R, Kiehlauch J, Walters M, Kallen A. 2017. Pan-Resistant New Delhi
399 Metallo-Beta-Lactamase-Producing *Klebsiella pneumoniae* - Washoe County, Nevada,
400 2016. Morb Mortal Wkly Rep 66.
- 401 8. World Health Organization. 2017. Prioritization of pathogens to guide resistant bacterial
402 infections, including tuberculosis. World Health Organization, Geneva, Switzerland.
- 403 9. Shon AS, Bajwa RPS, Russo TA. 2013. Hypervirulent (hypermucoviscous) *Klebsiella*
404 *pneumoniae*: A new and dangerous breed. Virulence 4:107–118.
- 405 10. Lam MMC, Wyres KL, Duchêne S, Wick RR, Judd LM, Gan Y-H, Hoh C-H, Archuleta S,
406 Molton JS, Kalimuddin S, Koh TH, Passet V, Brisse S, Holt KE. 2018. Population
407 genomics of hypervirulent *Klebsiella pneumoniae* clonal-group 23 reveals early emergence
408 and rapid global dissemination. Nat Commun 9:2703.
- 409 11. Nassif X, Sansonetti PJ. 1986. Correlation of the virulence of *Klebsiella pneumoniae* K1
410 and K2 with the presence of a plasmid encoding aerobactin. Infect Immun 54:603–608.
- 411 12. Martin MJ, Corey BW, Sannio F, Hall LR, MacDonald U, Jones BT, Mills EG, Harless C,
412 Stam J, Maybank R, Kwak Y, Schaufler K, Becker K, Hübner N-O, Cresti S, Tordini G,
413 Valassina M, Cusi MG, Bennett JW, Russo TA, McGann PT, Lebreton F, Docquier J-D.
414 2021. Anatomy of an extensively drug-resistant *Klebsiella pneumoniae* outbreak in
415 Tuscany, Italy. Proc Natl Acad Sci 118:e2110227118.
- 416 13. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, Chan EW-C, Shu L, Yu J, Zhang R,
417 Chen S. 2018. A fatal outbreak of ST11 carbapenem-resistant hypervirulent *Klebsiella*
418 *pneumoniae* in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis
419 18:37–46.
- 420 14. Wyres KL, Nguyen TNT, Lam MMC, Judd LM, van Vinh Chau N, Dance DAB, Ip M,
421 Karkey A, Ling CL, Miliya T, Newton PN, Lan NPH, Sengduangphachanh A, Turner P,
422 Veeraraghavan B, Vinh PV, Vongsouvath M, Thomson NR, Baker S, Holt KE. 2020.
423 Genomic surveillance for hypervirulence and multi-drug resistance in invasive *Klebsiella*
424 *pneumoniae* from South and Southeast Asia. Genome Med 12:11.
- 425 15. Gonzalez-Ferrer S, Peñaloza HF, Budnick JA, Bain WG, Nordstrom HR, Lee JS, Van Tyne
426 D. 2021. Finding Order in the Chaos: Outstanding Questions in *Klebsiella pneumoniae*
427 Pathogenesis. Infect Immun 89:e00693-20.
- 428 16. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, Jenney A, Connor
429 TR, Hsu LY, Severin J, Brisse S, Cao H, Wilksch J, Gorrie C, Schultz MB, Edwards DJ,
430 Nguyen KV, Nguyen TV, Dao TT, Mensink M, Minh VL, Nhu NTK, Schultsz C,

- Kuntaman K, Newton PN, Moore CE, Strugnelli RA, Thomson NR. 2015. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in *Klebsiella pneumoniae*, an urgent threat to public health. *Proc Natl Acad Sci* 112:E3574–E3581.
17. the EuSCAPE Working Group, the ESGEM Study Group, David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, Abudahab K, Goater R, Giani T, Errico G, Aspbury M, Sjunnebo S, Feil EJ, Rossolini GM, Aanensen DM, Grundmann H. 2019. Epidemic of carbapenem-resistant *Klebsiella pneumoniae* in Europe is driven by nosocomial spread. *Nat Microbiol* 4:1919–1929.
18. Marsh JW, Mustapha MM, Griffith MP, Evans DR, Ezeonwuka C, Pasculle AW, Shutt KA, Sundermann A, Ayres AM, Shields RK, Babiker A, Cooper VS, Van Tyne D, Harrison LH. 2019. Evolution of Outbreak-Causing Carbapenem-Resistant *Klebsiella pneumoniae* ST258 at a Tertiary Care Hospital over 8 Years. *mBio* 10:e01945-19.
19. Shropshire WC, Dinh AQ, Earley M, Komarow L, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Abbo L, Cober E, Revolinski S, Luterbach CL, Chambers H, Fowler VG, Bonomo RA, Shelburne SA, Kreiswirth BN, van Duin D, Hanson BM, Arias CA. 2022. Accessory Genomes Drive Independent Spread of Carbapenem-Resistant *Klebsiella pneumoniae* Clonal Groups 258 and 307 in Houston, TX. *mBio* 13:e00497-22.
20. Heiden SE, Hübner N-O, Bohnert JA, Heidecke C-D, Kramer A, Balau V, Gierer W, Schaefer S, Eckmanns T, Gattermann S, Eger E, Guenther S, Becker K, Schaufler K. 2020. A *Klebsiella pneumoniae* ST307 outbreak clone from Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron acquisition. *Genome Med* 12:113.
21. Falcone M, Giordano C, Barnini S, Tiseo G, Leonildi A, Malacarne P, Menichetti F, Carattoli A. 2020. Extremely drug-resistant NDM-9-producing ST147 *Klebsiella pneumoniae* causing infections in Italy, May 2020. *Eurosurveillance* 25:6.
22. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, Lam MMC, Duchêne S, Jenney A, Holt KE. 2019. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of *Klebsiella pneumoniae*. *PLOS Genet* 15:e1008114.
23. Waterman P, Kwak Y, Clifford R, Julius M, Onmus-Leone F, Tsurgeon C, Riley M, Black C, McGann P, Lesho E. 2012. A multidrug-resistance surveillance network: 1 year on. *Lancet Infect Dis* 12:587–588.
24. Galac MR, Snesrud E, Lebreton F, Stam J, Julius M, Ong AC, Maybank R, Jones AR, Kwak YI, Hinkle K, Waterman PE, Lesho EP, Bennett JW, Mc Gann P. 2020. A Diverse Panel of Clinical *Acinetobacter baumannii* for Research and Development. *Antimicrob Agents Chemother* 64:e00840-20.
25. Lebreton F, Snesrud E, Hall L, Mills E, Galac M, Stam J, Ong A, Maybank R, Kwak YI, Johnson S, Julius M, Ly M, Swierczewski B, Waterman PE, Hinkle M, Jones A, Lesho E,



- Bennett JW, McGann P. 2021. A panel of diverse *Pseudomonas aeruginosa* clinical isolates for research and development. JAC-Antimicrob Resist 3:dlab179.
26. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. 2005. Multilocus Sequence Typing of *Klebsiella pneumoniae* Nosocomial Isolates. J Clin Microbiol 43:4178–4182.
27. Lam MMC, Wick RR, Judd LM, Holt KE, Wyres KL. 2022. Kaptive 2.0: updated capsule and LPS locus typing for the *Klebsiella pneumoniae* species complex. Microbial Genomics 8:000800.
28. Follador R, Heinz E, Wyres KL, Ellington MJ, Kowarik M, Holt KE, Thomson NR. 2016. The diversity of *Klebsiella pneumoniae* surface polysaccharides. Microb Genomics 2.
29. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, Brisse S, Holt KE. 2018. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in *Klebsiella pneumoniae* populations. Microb Genomics 4.
30. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281.
31. Corkill JE, Cuevas LE, Gurgel RQ, Greensill J, Hart CA. SHV-27, a novel cefotaxime-hydrolysing β -lactamase, identified in *Klebsiella pneumoniae* isolates from a Brazilian hospital. Journal of Antimicrobial Chemotherapy 47:463-465.
32. Wise MG, Horvath E, Young K, Sahm DF, Kazmierczak KM. 2018. Global survey of *Klebsiella pneumoniae* major porins from ertapenem non-susceptible isolates lacking carbapenemases. J Med Microbiol 67:289–295.
33. Jacoby GA. 2009. AmpC β -Lactamases. Clin Microbiol Rev 22:161–182.
34. Clinical and Laboratory Standards Institute. 2018. Method for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Clin Lab Stand Inst 11th.
35. Centers for Disease Control and Prevention (U.S.). 2019. Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.).
36. The White House. 2015. National Action Plan For Combating Antibiotic-Resistant Bacteria. The White House, Washington, DC.
37. Brennan-Krohn T, Kirby JE. 2019. Synergistic Combinations and Repurposed Antibiotics Active against the Pandrug-Resistant *Klebsiella pneumoniae* Nevada Strain. Antimicrob Agents Chemother 63:e01374-19.

38. Opoku-Temeng C, Kobayashi SD, DeLeo FR. 2019. *Klebsiella pneumoniae* capsule polysaccharide as a target for therapeutics and vaccines. *Comput Struct Biotechnol J* 17:1360–1366.
39. Laforêt F, Antoine C, Blasdel Reuter B, Detilleux J, Pirnay J-P, Brisse S, Fall A, Duprez J-N, Delcenserie V, Thiry D. 2022. In Vitro and In Vivo Assessments of Two Newly Isolated Bacteriophages against an ST13 Urinary Tract Infection *Klebsiella pneumoniae*. *Viruses* 14:1079.
40. Pathogen genomics leading to vaccines. 2019. *Nat Genet* 51:923–923.
41. Lourenço M, Osbelt L, Passet V, Gravey F, Strowig T, Rodrigues C, Brisse S. 2022. Phages against non-capsulated *Klebsiella pneumoniae*: broader host range, slower resistance. preprint. *Microbiology*.
42. Hesse S, Rajaure M, Wall E, Johnson J, Bliskovsky V, Gottesman S, Adhya S. 2020. Phage Resistance in Multidrug-Resistant *Klebsiella pneumoniae* ST258 Evolves via Diverse Mutations That Culminate in Impaired Adsorption. *mBio* 11:e02530-19.
43. Orskov, I. D. A. & Fife-Asbury, M.A. 1977. New *Klebsiella* Capsular Antigen, K82, and the Deletion of Five of Those Previously Assigned. *Int. J. Syst, Bacteriol.* 27:386-387.
44. Clarke BR, Ovchinnikova OG, Kelly SD, Williamson ML, Butler JE, Liu B, Wang L, Gou X, Follador R, Lowary TL, Whitfield C. 2018. Molecular basis for the structural diversity in serogroup O2-antigen polysaccharides in *Klebsiella pneumoniae*. *J Biol Chem* 293:4666–4679.
45. Russo TA, MacDonald U, Hassan S, Camanzo E, LeBreton F, Corey B, McGann P. 2021. An Assessment of Siderophore Production, Mucoviscosity, and Mouse Infection Models for Defining the Virulence Spectrum of Hypervirulent *Klebsiella pneumoniae*. *mSphere* 6:e00045-21.
46. Kiaei S, Moradi M, hosseini-nave H, Ziasistani M, Kalantar-Neyestanaki D. 2018. Endemic dissemination of different sequence types of carbapenem-resistant *Klebsiella pneumoniae* strains harboring *bla_{NDM}* and 16S rRNA methylase genes in Kerman hospitals, Iran, from 2015 to 2017. *Infect Drug Resist* Volume 12:45–54.
47. Kim M-N, Yong D, An D, Chung H-S, Woo JH, Lee K, Chong Y. 2012. Nosocomial Clustering of NDM-1-Producing *Klebsiella pneumoniae* Sequence Type 340 Strains in Four Patients at a South Korean Tertiary Care Hospital. *J Clin Microbiol* 50:1433–1436.
48. AL-Quraini M, Rizvi M, AL-Jabri Z, Sami H, AL-Muzahmi M, AL-Muharrmi Z, Taneja N, AL-Busaidi I, Soman R. 2022. Assessment of In-Vitro Synergy of Fosfomycin with Meropenem, Amikacin and Tigecycline in Whole Genome Sequenced Extended and Pan Drug Resistant *Klebsiella Pneumoniae*: Exploring A Colistin Sparing Protocol. *Antibiotics* 11:153.

49. Pragasam AK, Shankar C, Veeraraghavan B, Biswas I, Nabarro LEB, Inbanathan FY, George B, Verghese S. 2017. Molecular Mechanisms of Colistin Resistance in *Klebsiella pneumoniae* Causing Bacteremia from India—A First Report. *Front Microbiol* 7:2135.
50. Gorrie CL, Mirčeta M, Wick RR, Judd LM, Lam MMC, Gomi R, Abbott IJ, Thomson NR, Strugnell RA, Pratt NF, Garlick JS, Watson KM, Hunter PC, Pilcher DV, McGloughlin SA, Spelman DW, Wyres KL, Jenney AWJ, Holt KE. 2022. Genomic dissection of *Klebsiella pneumoniae* infections in hospital patients reveals insights into an opportunistic pathogen. *Nat Commun* 13:3017.
51. Klaper K, Hammerl JA, Rau J, Pfeifer Y, Werner G. 2021. Genome-Based Analysis of *Klebsiella* spp. Isolates from Animals and Food Products in Germany, 2013–2017. *Pathogens* 10:573.
52. Liou VS, Goussard S, Guerineau V, Yoon E-J, Courvalin P, Galimand M, Grillot-Courvalin C. 2014. Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host. *RNA* 20:382–391.
53. Bontron S, Poirel L, Nordmann P. 2015. *In Vitro* Prediction of the Evolution of GES-1 β -Lactamase Hydrolytic Activity. *Antimicrob Agents Chemother* 59:1664–1670.
54. Jeong SH, Bae IK, Kim D, Hong SG, Song JS, Lee JH, Lee SH. 2005. First Outbreak of *Klebsiella pneumoniae* Clinical Isolates Producing GES-5 and SHV-12 Extended-Spectrum B-Lactamases in Korea. *Antimicrob Agents Chemother* 49:4809–4810.
55. Chen D-Q, Wu A-W, Yang L, Su D-H, Lin Y, Hu Y-W, Zheng L, Wang Q. 2016. Emergence and Plasmid Analysis of *Klebsiella pneumoniae* KP01 Carrying *bla*_{GES-5} from Guangzhou, China. *Antimicrob Agents Chemother* 60:6362–6364.
56. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. 2021. A genomic surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species complex. *Nat Commun* 12:4188.
57. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu C-H, McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W. 2019. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob Agents Chemother* 63:e00483-19.
58. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, Harris SR. 2017. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genomics* 3.
59. Jünemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, Mellmann A, Goesmann A, von Haeseler A, Stoye J, Harmsen D. 2013. Updating benchtop sequencing performance comparison. *Nat Biotechnol* 31:294–296.

60. Laing C, Buchanan C, Taboada EN, Zhang Y, Kropinski A, Villegas A, Thomas JE, Gannon VP. 2010. Pan-genome sequence analysis using Panseq: an online tool for the rapid analysis of core and accessory genomic regions. *BMC Bioinformatics* 11:461.
61. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics* 30:1312–1313.
62. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2. *Genome Biol* 20:257.
63. Low AJ, Koziol AG, Manninger PA, Blais B, Carrillo CD. 2019. ConFindr: rapid detection of intraspecies and cross-species contamination in bacterial whole-genome sequence data. *PeerJ* 7:e6995.
64. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 31:3691–3693.

A



C

		virulence score					
		0	1	2	3	4	5
resistance score	0	27	5	2	1	0	1
	1	28	5	1	2	1	1
	2	8	7	1	1	1	0
	3	3	4	1	0	0	0

Isolate	ST	Genes
582610	268	ybt, clb, iuc, iro, rmpA, rmpA2, CTX-M-15
515432	1399	ybt, iuc, rmpA2, CTX-M-15, SHV-12
752729	147	ybt, iuc, rmpA, rmpA2, CTX-M-15, NDM-1
5881	48	iuc, rmpA2, CTX-M-15
365679	2071	iuc, CTX-M-15, NDM-1
731029	37	iuc, CTX-M-14

Figure 1




Figure 2

Figure Legends

Figure 1. Genomic diversity of *K. pneumoniae* in the MRSN collection A) cgMLST minimum spanning tree of the 3,123 *K. pneumoniae* genomes. Isolates with an identical MLST profile are represented within a single circle. Initial subset of isolates selected are indicated by filled red circles ($n = 346$) and the final panel isolates are indicated by filled purple circles ($n = 100$). B) Core genome SNP phylogenetic tree of 346 *K. pneumoniae* isolates initially selected to represent the breadth of *K. pneumoniae* diversity. The final 100 isolates selected for the panel are indicated in purple triangles. C) Heatmap indicating the combination of virulence/resistance scores for all panel isolates. *In silico* prediction using the Kleborate typing tool and visual inspired from Lam and coauthors (54). The number of isolates with a specific score are indicated in the boxes. Convergent isolates are indicated by the dashed black box and listed in the table below. All convergent isolates are carrying the *iuc* loci and an ESBL and/or carbapenemase gene.

Figure 2. Characteristics of the *K. pneumoniae* diversity panel. Core genome SNP-based phylogenetic tree of the 100 genomes in the final diversity panel. Sequence-type (ST), virulence score (see legend), capsule polysaccharide locus, KL-type, and AMR status (see legend and text for additional details) are indicated in the columns. The assigned antimicrobial resistance phenotype for each antibiotic tested is indicated by the maroon squares- a result of non-susceptible (filled) or susceptible (open). The light blue circles indicate the presence of a known antimicrobial resistance gene, and the orange circles indicate the presence of a known mutation/truncation. AMK, amikacin; GEN, gentamicin; TOB, tobramycin; ATM, aztreonam; SAM, ampicillin/sulbactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; CZA, ceftazidime/avibactam; C/T ceftolozane/tazobactam; IPM, imipenem; MEM meropenem; CIP,

614 ciprofloxacin, LVX, levofloxacin; TZP, piperacillin/tazobactam; SXT, Sulfamethoxazole-
615 Trimethoprim; TET, Tetracycline; TGC, Tigecycline.